Literature Collection

BACKGROUND: Conversational agents (CAs) are increasingly used as a promising tool for scalable, accessible, and personalized self-management support of people with a chronic disease. Studies of CAs for self-management of chronic disease operate within a multidisciplinary domain: self-management originates from (behavioral) psychology and CAs stem from intervention technology, while diseases are typically studied within the biomedical context. To ensure their effectiveness, structured evaluations and descriptions of the interventions, integrating biomedical, behavioral, and technological perspectives, are essential. OBJECTIVE: We aimed to examine the design and evaluation of CAs for self-management support of chronic diseases, focusing on their characteristics, integration of behavioral change techniques, and evaluation methods. The findings will guide future research and inform intervention design. METHODS: We conducted a systematic search in the PubMed and Embase databases to identify studies that investigated CAs for chronic disease self-management, published from January 1, 2018, to April 15, 2024. Full-text journal articles, published in English, studying the efficacy or effectiveness of a CA in the context of self-management for chronic diseases in adults were included. Data extraction was guided by conceptual frameworks to ensure comprehensive reporting of intervention and methodologies: the behavioral intervention technology model and the CONSORT-EHEALTH (Consolidated Standards of Reporting Trials of Electronic and Mobile Health Applications and Online Telehealth) checklist. Risk of bias was assessed using the Risk of Bias 2 tool and the Risk of Bias in Non-randomized Studies-of Interventions (ROBINS-I) tool (version 2). RESULTS: In total, 25 studies were included, primarily focusing on text-based, rule-based CAs delivered via a mobile apps. The chronic diseases predominantly targeted were diabetes and cancer. Commonly identified clusters of behavior change techniques were "shaping knowledge," "feedback and monitoring," "natural consequences," and "associations." However, reporting of behavior change techniques and their delivery was lacking, and intervention descriptions were limited. Studies were mostly in the early phase, with a great variety in intervention descriptions, study methods, and outcome measures. CONCLUSIONS: Advancing the field of CA-based interventions requires transparent intervention descriptions, rigorous methodologies, consistent use of validated scales, standardized taxonomy, and reporting aligned with standardized frameworks. Enhanced integration of artificial intelligence-driven personalization and a focus on implementation in health care settings are critical for future research.

Patients treated for drug addiction have high asthma and COPD prevalence rates. The relative contributions of cigarette smoking, smoking intensity and possible smoking of other substances has not been described. We aimed to describe the prevalence and determinants of asthma and COPD in patients prescribed methadone as opioid substitution therapy (OST). In a cross-sectional study of an anonymised patient-level primary care dataset of UK inner-city general practices (n = 46), 321,395 patients aged ≥18 years were identified. A total of 676 (0.21%) had a record of a methadone ever issued in primary care. The association between respiratory disease and methadone prescribing was examined using logistic regression. Models were adjusted for potential effects of clustering by practice. A total of 97.3% of patients prescribed methadone were cigarette smokers, either current (81.2%) or ex-smokers (16.1%). The prevalences of asthma and COPD were higher in methadone patients (14.2% and 12.4%, respectively) compared to non-methadone patients (4.4% and 1.1%, respectively). Methadone was an independent determinant of asthma, adjusting for smoking status (OR 3.21; 95% CI: 2.52, 4.10) or for smoking intensity (3.08; 2.27, 4.19), and of COPD, adjusting for smoking status (6.00; 4.61, 7.80) or for smoking intensity (5.80; 4.12, 8.17). COPD and asthma prevalence were substantially higher in those prescribed methadone compared to those never prescribed methadone. Prescription of methadone was an independent predictor for both COPD and asthma, even after adjustment for smoking status and smoking intensity. Possible explanations include confounding by association with smoking of heroin or crack cocaine, both of which may have a causal association with COPD and asthma.

Anxiety and depression are common comorbidities in patients with chronic obstructive pulmonary disease (COPD), which can contribute to increased morbidity, reduced quality of life, and worse clinical outcomes. Nevertheless, these psychological conditions remain largely overlooked. This narrative review includes studies published between 1983 and 2025 to synthesise the current evidence on the risk factors, clinical impacts, and therapeutic strategies for these comorbidities. While the exact mechanisms leading to their increased prevalence are not fully understood, growing evidence implicates a combination of biological (e.g., systemic inflammation), social (e.g., isolation and stigma), and behavioural (e.g., smoking and inactivity) factors. Despite current guidelines recommending the identification and management of these comorbidities in COPD, they are not currently included in COPD assessments. Undetected and unmanaged anxiety and depression have serious consequences, including poor self-management, non-adherence to medications, increased risk of exacerbation and hospitalisations, and even mortality; thus, there is a need to incorporate screening as part of COPD assessments. There is robust evidence showing that pulmonary rehabilitation, a core non-pharmacological intervention, can improve mood symptoms, enhance functional capacity, and foster psychosocial resilience. Psychological therapies such as cognitive behavioural therapy (CBT), mindfulness-based approaches, and supportive counselling have also demonstrated value in reducing emotional distress and improving coping mechanisms. Pharmacological therapies, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are commonly prescribed in moderate to severe cases or when non-pharmacological approaches prove inadequate. However, the evidence for their efficacy in COPD populations is mixed, with concerns about adverse respiratory outcomes and high discontinuation rates due to side effects. There are also barriers to optimal care, including underdiagnosis, a lack of screening protocols, limited provider training, stigma, and fragmented multidisciplinary coordination. A multidisciplinary, biopsychosocial approach is essential to ensure early identification, integrated care, and improved outcomes for patients with COPD.